Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 155 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metastases to the Brain Clear all
Active, not recruiting Phase 1 Interventional

A Study of LN-144 in People With Metastatic Melanoma to the Brain

NCT05640193
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Lifileucel (LN-144)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Withdrawn Phase 1 Interventional

Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases

NCT00738335
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
erlotinib hydrochloride, immunoenzyme technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study, stereotactic radiosurgery
Drug · Other · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases

NCT03680144
View directory record Official record
Conditions
Invasive Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Dynamic Susceptibility Contrast-MRI (DSC-MRI), Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

NCT00002752
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
iodine I 131 monoclonal antibody 81C6
Radiation
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 6, 2026, 9:42 AM EDT
Recruiting Phase 1 Interventional

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

NCT07698899
View directory record Official record
Conditions
Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
Interventions
25 mCi 177Lu- DTPA-omburtamab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 22 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

NCT02132598
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Interventions
cabozantinib
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 6, 2026, 9:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

NCT06907043
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
EIK1004-001 (IMP1707-001)
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years to 89 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 6, 2026, 9:42 AM EDT
Active, not recruiting Phase 1 Interventional

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

NCT04661384
View directory record Official record
Conditions
Ependymoma, Glioblastoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the Leptomeninges
Interventions
IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Recruiting Phase 1 Interventional

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

NCT07158905
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease
Interventions
AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg, Placebo
Biological · Other
Lead sponsor
Institute for Molecular Medicine
Other
Eligibility
65 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Boca Raton, Florida • Miami Lakes, Florida • Stuart, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

NCT02521051
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Alectinib, Bevacizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis

NCT01508221
View directory record Official record
Conditions
Brain Metastasis
Interventions
Trental, Vitamin E
Drug · Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Carmustine Implants in Treating Patients With Brain Metastases

NCT00003878
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
polifeprosan 20 with carmustine implant, conventional surgery
Drug · Procedure
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
11
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors

NCT00541138
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, tamoxifen citrate, topotecan hydrochloride, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 6, 2026, 9:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094
View directory record Official record
Conditions
Advanced Solid Tumors, HER2-positive Breast Cancer
Interventions
ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Cerritos, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neurocognitive Decline in Patients With Brain Metastases

NCT03508752
View directory record Official record
Conditions
Brain Metastases
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Active, not recruiting Phase 3 Interventional

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

NCT04804644
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
227
States / cities
Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Physical and Mental Practice for Bimanual Coordination Rehabilitation

NCT03817086
View directory record Official record
Conditions
Traumatic Brain Injury, Weakness, Muscle, Coordination Impairment
Interventions
Hand coordination and mental practice, Hand coordination and action observation
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
20 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 6, 2026, 9:42 AM EDT
Completed No phase listed Observational

Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor

NCT00001148
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Glioma
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 9:42 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

NCT06777433
View directory record Official record
Conditions
Brain Metastases From Solid Tumors
Interventions
RAD101 (18F-FPIA)
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Hoffman Estates, Illinois • Goshen, Indiana • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 6, 2026, 9:42 AM EDT
Completed No phase listed Observational

Sensitivity to Change of the Lower Extremity Functional Scale in Patients With Stroke

NCT01536990
View directory record Official record
Conditions
Lower Extremity Dysfunction, Stroke
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 6, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

NCT04410133
View directory record Official record
Conditions
Brain Metastases
Interventions
18F fluciclovine
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 6, 2026, 9:42 AM EDT
Withdrawn Phase 2 Interventional

Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT02014545
View directory record Official record
Conditions
Brain Metastases, Non-small Cell Lung Cancer
Interventions
Lucanthone, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 6, 2026, 9:42 AM EDT